Clinical Trials Logo

Clinical Trial Summary

Pulse pressure variation (PPV) is a well-known and widely used dynamic preload indicator based on heart-lung interaction to predict fluid responsiveness. Generally, patients are considered to be fluid-responsive when the PPV value larger than 11-13%. However, several previous researches demonstrated that there is a zone of uncertainty (grey zone) in PPV. To predict fluid-responsiveness accurately in the patients with PPV within grey zone (9-13%), the investigators would evaluate the augmented PPV using augmented ventilation.


Clinical Trial Description

n/a


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02653469
Study type Observational
Source Samsung Medical Center
Contact
Status Completed
Phase N/A
Start date September 2015
Completion date February 2016

See also
  Status Clinical Trial Phase
Recruiting NCT05185947 - Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer Phase 2
Completed NCT02309944 - Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients N/A
Withdrawn NCT00328757 - Safety of Regular Diet as the First Meal in Patients Who Underwent Surgical Treatment for Gynecologic Cancer Phase 3
Completed NCT02728830 - A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers Early Phase 1
Completed NCT02935530 - Thromboprophylaxis After Surgery for Gynecologic Malignancy in China Phase 3
Completed NCT02918461 - Emerging From the Haze for Gynecologic Cancer Survivors N/A
Completed NCT02786524 - Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy N/A
Terminated NCT04493619 - PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Phase 1/Phase 2
Completed NCT03101280 - A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer Phase 1